Back to Search
Start Over
PDK1 is Expressed in Ovarian Serous Carcinoma and Correlates with Improved Survival in High-grade Tumors.
- Source :
-
Anticancer research [Anticancer Res] 2015 Nov; Vol. 35 (11), pp. 6329-34. - Publication Year :
- 2015
-
Abstract
- Background/aim: 3-Phosphoinositide-dependent protein kinase-1 (PDK1) mediates the cellular effects of various growth factors. Increased PDK1 expression is present in various cancers, suggesting that PDK1 may be a critical oncogene in cancer progression. However, only limited data exist on PDK1 expression in ovarian serous cancer.<br />Materials and Methods: We used tissue microarrays to analyze PDK1 expression in 253 primary ovarian serous carcinoma samples.<br />Results: A statistically significant negative correlation between PDK1 expression and tumor grade was found. In the high-grade group of ovarian serous carcinomas (n=189), there was a statistically significant difference in overall survival between cases with positive and negative PDK1 expression (p=0.035); positive cases showed longer overall survival. Multivariate analysis confirmed that slight PDK1 expression was an independent indicator for prolonged overall survival (HR=0.51, 95% CI=0.28-0.92, p=0.025).<br />Conclusion: PDK1 appears to be a prognostic marker and a possible therapeutic target in ovarian serous carcinoma.<br /> (Copyright© 2015 International Institute of Anticancer Research (Dr. John G. Delinassios), All rights reserved.)
- Subjects :
- Cystadenocarcinoma, Serous metabolism
Cystadenocarcinoma, Serous pathology
Female
Humans
Immunoenzyme Techniques
Middle Aged
Neoplasm Grading
Ovarian Neoplasms metabolism
Ovarian Neoplasms pathology
Prognosis
Pyruvate Dehydrogenase Acetyl-Transferring Kinase
Survival Rate
Tissue Array Analysis
Biomarkers, Tumor metabolism
Cystadenocarcinoma, Serous mortality
Ovarian Neoplasms mortality
Protein Serine-Threonine Kinases metabolism
Subjects
Details
- Language :
- English
- ISSN :
- 1791-7530
- Volume :
- 35
- Issue :
- 11
- Database :
- MEDLINE
- Journal :
- Anticancer research
- Publication Type :
- Academic Journal
- Accession number :
- 26504072